Anti-CD123-anti-CD3 bispecific antibody - Janssen Research & Development

Drug Profile

Anti-CD123-anti-CD3 bispecific antibody - Janssen Research & Development

Alternative Names: Ab-178

Latest Information Update: 12 May 2016

Price : $50

At a glance

  • Originator Janssen Research & Development
  • Class Monoclonal antibodies; Small molecules
  • Mechanism of Action CD3 antigen inhibitors; Interleukin-3-receptor-alpha-subunit-antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute myeloid leukaemia

Most Recent Events

  • 16 Apr 2016 Preclinical trials in Cancer in USA (Parenteral) prior to April 2016
  • 16 Apr 2016 Pharmacodynamics data from preclinical studies in Acute myeloid leukaemia presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top